Holding(s) in Company
12 April 2024
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
We announced our results for the financial year ended 30 June 2023 on Monday 30 October.
£ 0 M
Revenue increased by 9% to £12.82 million
(2022: £11.72 million)
£ 0 M
PBT up by 9% to £10.13m
(2022: £9.28m)
An overview of our half year results with key financials and the future outlook.
£12.816 Million
£10.033 Million
160.63 pence
Release of the unaudited accounts for the ½ year from 1st July 2023 to 31st December 2023
Release of the audited accounts for the full year from 1st July 2023 to 30th June 2024
Bioventix’s shares are traded on the Alternative Investment Market with the symbol BVXP. Click the link to go to our AIM page.
Cavendish Capital Markets Limited (Cavendish) are our Nominated Advisor and Stock Broker. If you wish to buy shares in Bioventix plc please contact your stockbroker.
You can also get further information from the London Stock Exchange AIM website.
12 April 2024
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
25 March 2024
Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results for the six months ended 31 December 2023 …
29 January 2024
Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development…
4 April 2024
Interim Report and Financial Statements for the 6 months to 31 December 2023 To download this report as…
10 November 2023
Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for…
30 October 2023
Director’s report and financial statements for the year ended 30th June 2023. To download this report as a PDF…
This site contains key corporate, financial and shareholder information for Bioventix plc. The information disclosed is for the purposes of AIM Rule 26.
Last updated 15 March 2024
Bioventix plc is subject to the UK City Code on Takeovers and Mergers.
Address |
7 Roman’s Business Park, East Street, Farnham, Surrey GU9 7SX |
Company Number |
4923945 |
VAT Number |
GB 822 6186 34 |
Country of Incorporation/Company Operation |
United Kingdom |
Registered Office |
Cargil Management Services Ltd |
Key Business |
Healthcare, Diagnostics |
Key Products |
Sheep Monoclonal Antibodies |
Constitutional Documents |
Directors |
Ian James Nicholson, Non-Executive Chairman Peter John Harrison, Chief Executive Officer Bruce Edward Heath Hiscock, Chief Finance Officer Nicholas John McCooke, Non-Executive Director Joanne Patra Pisani, Non-Executive Director All of: Bioventix Plc, 7 Romans Business Park, East Street, Farnham, Surrey, GU9 7SX |
Nominated Adviser & Broker |
Cavendish Capital Markets Limited (Cavendish) |
Reporting Accountant & Auditor |
Kreston Reeves LLP 2nd Floor 168 Shoreditch High Street, London, E1 6RA |
Registrars |
Share Registrars Limited, The Courtyard, 17 West Street, Farnham GU9 7DR |
Remuneration Committee |
Nick McCooke (Chair) |
Audit Committee |
Jo Pisani (Chair) |
Nomination Committee |
Nick McCooke (Chair) |
Primary Trading Exchange |
London Stock Exchange AIM |
Other exchanges or trading platforms where shares traded |
None |
Share Identification Ticker |
AIM:BVXP |
ISIN |
GB00B4QVDF07 |
SEDOL |
B4QVDF0 |
Share Type and Value |
Ordinary Shares £0.05 each |
Number of Securities in Issue |
5,209,333 |
Percentage of shares not in public hands |
48% |
Restrictions on transfer of shares |
None |
Sanford DeLand |
12.8% |
Gresham House |
11.1% |
Liontrust |
11.0% |
Hargreaves Lansdown Stockbrokers |
6.6% |
Rathbone Investment Management (inc. Investec) |
6.2% |
Peter Harrison |
5.7% |
Danske Bank |
2.9% |
Hargreaves Lansdown Fund Managers |
2.3% |
Edentree Investment Management |
2.1% |
Charles Stanley |
1.9% |
Schroder Investment Management |
1.3% |
Bioventix plc is committed to maintaining high standards of corporate governance and has adopted the QCA Corporate Governance Code (“the Code”). The Board has reviewed the corporate governance framework that Bioventix plc operates and considers it to be effective and proportional to the size, risks, complexity and operations of Bioventix plc and reflective of the company’s culture and values. Details of how Bioventix plc complies with the Code can be found in the Corporate Governance Statement contained on pages 36-56 of the Annual Report.
Terms of Reference for Bioventix plc Board Committees are as follows: